We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+32.01%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$288M
AUM Growth
+$69.6M
Cap. Flow
+$25.3M
Cap. Flow %
8.77%
Top 10 Hldgs %
62.41%
Holding
37
New
13
Increased
8
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$17.2M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$15M
3
MRK icon
Merck
MRK
+$14.7M
4
BAX icon
Baxter International
BAX
+$12.9M
5
MRUS
Merus
MRUS
+$11.6M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$26M
2
GEHC icon
GE HealthCare
GEHC
+$13.3M
3
BIIB icon
Biogen
BIIB
+$11.9M
4
CTLT
CATALENT, INC.
CTLT
+$11.8M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.08M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$37.3B
$31.3M 10.84%
2,216,188
+421,853
+24% +$5.32M
AVDL
2
DELISTED
Avadel Pharmaceuticals
AVDL
$20.1M 6.97%
1,189,511
+349,578
+42% +$5.21M
SILK
3
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$19.9M 6.88%
+1,083,605
New +$17.2M
NTRA icon
4
Natera
NTRA
$38.9B
$17.4M 6.03%
190,114
+48,267
+34% +$3.63M
ASND icon
5
Ascendis Pharma A/S
ASND
$17.1B
$17M 5.91%
112,670
+13,120
+13% +$1.87M
LEGN icon
6
Legend Biotech
LEGN
$4.31B
$15.9M 5.52%
283,773
+181,558
+178% +$10.9M
MRK icon
7
Merck
MRK
$315B
$15.7M 5.45%
+119,200
New +$14.7M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$123B
$14.9M 5.16%
+35,598
New +$15M
MDGL icon
9
Madrigal Pharmaceuticals
MDGL
$12.8B
$14.2M 4.94%
53,355
+27,831
+109% +$6.56M
BAX icon
10
Baxter International
BAX
$11.7B
$13.6M 4.71%
+317,566
New +$12.9M
MRUS
11
DELISTED
Merus
MRUS
$12.9M 4.47%
+286,322
New +$11.6M
TNDM icon
12
Tandem Diabetes Care
TNDM
$1.17B
$11.6M 4.01%
+326,506
New +$8.75M
ARGX icon
13
argenx
ARGX
$53.8B
$11M 3.82%
27,981
+3,799
+16% +$1.47M
XENE icon
14
Xenon Pharmaceuticals
XENE
$6.6B
$8.93M 3.1%
207,465
-18,099
-8% -$833K
REGN icon
15
Regeneron Pharmaceuticals
REGN
$70.9B
$8.25M 2.86%
8,567
-7,445
-46% -$7.08M
AXSM icon
16
Axsome Therapeutics
AXSM
$11.8B
$8.2M 2.84%
102,711
-28,027
-21% -$2.35M
PRAX icon
17
Praxis Precision Medicines
PRAX
$8.77B
$6.5M 2.25%
106,494
-142,267
-57% -$6.38M
EXAS
18
DELISTED
Exact Sciences
EXAS
$6.22M 2.16%
+90,000
New +$5.69M
LYRA
19
DELISTED
LYRA THERAPEUTICS INC
LYRA
$6.09M 2.11%
+19,576
New +$5.22M
ATXS
20
DELISTED
Astria Therapeutics
ATXS
$5.2M 1.8%
369,549
-173,396
-32% -$2.16M
INSP icon
21
Inspire Medical Systems
INSP
$1.46B
$5.06M 1.76%
+23,566
New +$4.62M
ALPN
22
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.78M 1.66%
+120,687
New +$3.56M
ARCT icon
23
Arcturus Therapeutics
ARCT
$172M
$4.69M 1.63%
138,927
+28,457
+26% +$1.01M
ARQT icon
24
Arcutis Biotherapeutics
ARQT
$3.56B
$4.46M 1.55%
+449,694
New +$3.36M
DFTX
25
Definium Therapeutics
DFTX
$5.88B
$3.57M 1.24%
+379,596
New +$2.16M
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
LS
Leelyn Smith Geneva, Illinois $713M AUM 17.46% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Tri Locum Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Tri Locum Partners held 37 positions worth $288M, up 32% from $219M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Tri Locum Partners deployed $25.3M of net new capital in Q1 2024, opening 13 new positions and adding to 8 existing holdings. Its largest new stake was Silk Road Medical, Inc. Common Stock: 1,083,605 shares worth $19.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $7.08M trimmed.

  • Tri Locum Partners's largest Q1 2024 buy was Silk Road Medical, Inc. Common Stock: 1,083,605 shares worth $19.9M.
  • Tri Locum Partners added most to Legend Biotech in Q1 2024, an estimated $10.9M increase.
  • Tri Locum Partners's biggest Q1 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $7.08M.
  • Tri Locum Partners fully exited AbbVie in Q1 2024, selling an estimated $26M.
  • Tri Locum Partners's ten largest holdings make up 62% of its $288M portfolio in Q1 2024.
  • Tri Locum Partners opened 13 new positions and closed 10 in Q1 2024.
  • Tri Locum Partners's portfolio value rose 32% quarter-over-quarter to $288M.

Based on Tri Locum Partners's 13F filing for Q1 2024, filed 15 May 2024.